Tag Archives: Chemotherapy

Aktuelle Nachrichten Finanzen/Wirtschaft Gesundheit/Medizin Internationales Marketing/Werbung

Global Uveal Melanoma Therapeutics Market Size, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024

Global Uveal Melanoma Therapeutics Market: By Disease Type (Choroidal Melanomas, Iris Melanomas, and Ciliary Body Melanomas), By Treatment Type (Chemotherapy, Immunotherapy, and Targeted Therapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024


Global uveal melanoma therapeutics market was valued at US$ XX Mn in 2017 and expected to grow at XX% Compound Annual Growth Rate (CAGR) from 2018 to 2024


Market Outline: Uveal Melanoma Therapeutics Market

Uveal melanoma is a disease in which malignant (cancer) cells form in the tissues of the eye. The tumors arise from the melanocytes that reside within the uvea giving color to the eye. Uveal melanoma begins between the three layers of the wall of the eye. The first layer (outer layer) includes sclera and the cornea at the front of the eye. The inner layer has a retina, that senses light and send images. The middle layer is the layer in which the melanoma forms. This layer is called as uvea.

Increase in the prevalence of uveal melanoma is driving the growth of the market. The rising awareness among the people regarding the disease among healthcare fraternity is anticipated to drive the growth of the uveal melanoma therapeutics market. However, the higher cost of the therapy and reimbursement policies are may constrain the growth of the market.


Free sample of this report is available upon request @



Market Scope: Uveal Melanoma Therapeutics Market

Uveal melanoma therapeutics market is segmented based on the disease type, treatment type, and distribution channel.

Based on the disease type, the market is segmented into the following:

  • Choroidal Melanomas
    • Small Melanomas
    • Medium-sized Melanomas
    • Large Melanomas
  • Iris melanomas
  • Ciliary Body Melanomas

Based on the treatment type, the market is segmented into the following:

  • Chemotherapy
    • Methotrexate
    • Others
  • Immunotherapy Drugs
    • Pembrolizumab
    • Ipilimumab
    • Others
  • Targeted Drugs

Based on the distribution channel, the market is segmented into the following:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies


Free TOC of this report is available upon request @



Regional Analysis:  Uveal Melanoma Therapeutics Market

Geographically, global uveal melanoma therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America uveal melanoma therapeutics market is driven by increase in the prevalence of the eye related disorders. The growing patient population with uveal melanoma disorder expected fuel the market growth in the region. According to the American Cancer Society, about nine of 10 melanomas of the eye develop in the choroid. It also states that 2,730 new cases were detected in 2014 of uveal melanoma in the U.S.


Competition Assessment: Uveal Melanoma Therapeutics Market

Some of the players in the global uveal melanoma therapeutics market include:

  • Eli Lilly & Co. (U.S)
  • Novartis AG (Switzerland)
  • AstraZeneca plc (UK)
  • Pfizer, Inc. (U.S)
  • Merck (U.S)
  • Roche (Switzerland)
  • Amgen (U.S)
  • Bayer (Germany)
  • Spectrum Pharmaceuticals, Inc. (U.S)


Ask Analyst for Full Information about this report @



Notable Market Developments: Uveal Melanoma Therapeutics Market

  • Bristol-Myers Squibb and National Cancer Institute (NCI) completed the phase II study of Nivolumab in combination with Ipilimumab for Uveal Melanoma


Get access to full summary @



About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,

152 – 160 City Road,

London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US):+1-866-598-1553

Website @https://www.precisionbusinessinsights.com



Explore the novel trends in Cancer at Cancer Therapy Meeting 2018

May 2nd, 2018 United Kingdom: ConferenceSeries llc LTD, host of Experts Meet on Cancer Therapy 2018, the Conference that discusses the Advanced trends for the future of Cancer and its treatment.

Cancer Therapy Meeting 2018 slated during November 14- 15, 2018 at Melbourne, Australia will schedule and coordinate all meetings with our Editorial Board Members and other experts in the oncology, cancer science & Cancer Therapy fields across the world. The Cancer Therapy Meeting scientific program paves a way to gather latest information through the research talks and presentations and put forward many thought provoking strategies in Cancer Conference.

The scientific program will focus on current advances in the research and leading strategies in Oncology and cancer medicine and its development with a theme “Sensible assembly on emerging aspects of Cancer therapy” and the conference highlights are:  Cancer, Most Prevalent Cancers, Stages of cancer, Main causes of cancer, Signs & symptoms of different cancers, Natural Methods for treatment of cancer, Management of cancer, Surgery, Radiation therapy , Immunotherapy, Hormonal Therapy.

Cancer is one of the leading causes of Morbidity and Mortality worldwide. The Number of new cases is expected to rise about by 70% over the next 2 decades. Approximately 70% of deaths from cancer occur in low and middle-income countries. Tobacco use is the most important risk factor for cancer and is responsible for 22% of cancer deaths.

In addition, attendees will enjoy special events and lecturers featuring specialists and top scholars. It is a perfect platform for Cancer educators, practitioners and researchers to exchange & share their experiences, research findings about all aspects of Oncology and Cancer Sciences.

This year Cancer Therapy meeting 2018 is officially collaborated with The PACRA (Pan- Asian Clinical Research Association) is headquartered in Singapore. PACRA was born out of the recognition that whilst there are several organizations offering a variety of training and education resources / services to clinical research professionals on a global basis, there was no single organization providing such resources / services with a dedicated focus on Asia. PACRA will therefore focus its efforts on the enhancement of all aspects of clinical research training / education and news / information within this defined geographical remit. PACRA’s training and education will be managed on a demand driven basis.


Conference Highlights:

300+ Participation (70 Industry: 30 Academia)

5+ Keynote Speakers

50+ Plenary Speakers

20+ Exhibitors

14 Innovative Educational Sessions

5+ Workshops

B2B Meetings

Conference is offering Exhibition and Sponsorship opportunity for the interested organizations.

If you would like to know more information about this conference, to book a slot, Sponsorship and Exhibit sales information, please Contact:  Bella Swan

Tel.: +1-650-889-4686

Email: cancertherapy@annualcongress.net   or visit: https://cancertherapy.cancersummit.org/


Gesundheit/Medizin Pressemitteilungen

Radioimmunotherapy Market : Global Industry Analysis and Opportunity Assessment 2022

Bharat Book Bureau Provides the Trending Market Research Report on „Global Radioimmunotherapy Market, Forecast to 2022“ under Life Sciences category. The report provides information on industry overview, market size, latest developments, industry trends, key players, global presence, and their future prospects.

Global Radioimmunotherapy Market , Dosage, Price & Clinical Pipeline Outlook 2022″ Report Highlights:

– Need & Efficacy of Radioimmunotherapy
– Components of Radioimmunotherapy
– Clinical Status of Radioimmunotherapy in Various Cancer Therapy
– Emerging Opportunities in the Radioimmunotherapy Segment
– Patent, Dosage & Price Analysis
– Antibodies in radioimmunotherapy
– Global Radioimmunotherapy Clinical Pipeline: 68 Drugs
– Clinical Pipeline analysis by Phase

Request a free sample copy of Radioimmunotherapy Market Report @ https://www.bharatbook.com/request-sample/736101 Cancer therapy is one of the most intensive areas of research globally. The severity and prevalence associated with cancer makes it one of the most feared ailments worldwide. The prevalence of cancer globally which is bound to become a global burden in the coming decades. This has led to an increase in efficacy and less toxicity. 

Immunotherapy is being anticipated as being the most promising and viable segment of modern cancer therapeutics. Cancer Immunotherapy is the body’s own immune system to treat cancer. Years of research has proved that the immune system can be used to identify and eliminate particular cells from the body. This unique property of the immune system has been widely used to treat diseases by modulating immune responses.

The radioimmunotherapy treatment was then carried out as a radioactive therapy therapy. Also, as the non-Hodgkin’s lymphoma, the amalgamation of radiation therapy with immunotherapy proved to be a breakthrough method of cancer therapy with impressive results in cancers. which was earlier considered to be a non-treatable cancer.

Ibritumomab tiuxetan and iodine (131I) tositumomab are the two most popular radioimmunotherapeutics that received FDA approval in the year 2002 and 2003 respectively. As of now, only two radioimmunotherapeutics have been globally marketed for the treatment of non-Hodgkin’s lymphoma under the brand name Zevalin (Ibriumomab tiuxetan) and Bexxar (Tositumomab).

Radioimmunotherapy in the past & current research has progressed rapidly to become more and more of a clinical and commercial aspect. Although it has been approved as a standard treatment for non-Hodgkin lymphoma and follicular lymphoma, it has yet to prove its clinical efficacy in other cancer types.

Radioimmunotherapy presents an optimistic picture regarding its improvement with efficacy. With the advancement in science and technology, the Radioimmunotherapy segment is bound to progress at a rapid rate thus making it a promising cancer therapeutic of the future.

Global Radioimmunotherapy aims at providing in-depth analysis of the market with special focus on the global market size, current market trend and factors affecting the future market growth. The radioimmunotherapy market provides a detailed insight into the radioimmunotherapy marketed products.

Read the full report  : https://www.bharatbook.com/healthcare-market-research-reports-736101/global-radioimmunotherapy-dosage.html About Bharat Book Bureau:

Bharat Book Bureau is the leading market research report provider for market research reports, company profiles, industry reports, country reports, business reports, newsletters and online databases. Bharat Book Bureau delivers more than 400 publishers around the globe. We cover ourselves from Aeronautics to Zoology.

Contact us at: Bharat Book Bureau  Phone : +91 22 27810772/27810773 Email : poonam@bharatbook.com Website : www.bharatbook.com Follow us on : Twitter, Facebook, LinkedIn, Google Plus

Aktuelle Nachrichten Gesundheit/Medizin Pressemitteilungen

Metastatic Cancer Drug Market : Global Industry Analysis and Opportunity Assessment 2022

Bharat Book Bureau Provides the Trending Market Research Report on „Global Metastatic Cancer Drug Market, Forecast to 2022“ under Life Sciences category. The report provides information on industry overview, market size, latest developments, industry trends, key players, global presence, and their future prospects.

Global Metastatic Cancer Drug Market , Dosage, Price & Clinical Pipeline Outlook 2024″ Report Highlights:

– Drug Patent, Availability, Price & Dosage Analysis
– Market Analysis of Metastatic Cancer
– Management Approaches for Metastatic Cancer by Type
– Global Cancer Metastases Clinical Pipeline Overview : 66 Drugs
– Marketed Cancer Metastases Drugs Clinical Insight: 14 Drugs
– Future Perspective of Metastatic Cancer Market

Request a sample copy of Metastatic Cancer Drug Market Report @ https://www.bharatbook.com/request-sample/338296 

Cancer is a complex disease which results in uncontrolled cell growth in any region or organ of the body. Cancer is segmented into different stages depending on the spread of tumor cells within the body. Primary stages of cancer involve the uncontrolled growth of cancer cells within a confined region or organ of a body. In one or more organs after being treated in one organ or cancer cells metastasizes or moves from one organ to another. Search conditions are termed metastatic cancers. For instance, breast cancer or metastasis of breast cancer is not known.

In 2017, 600920 deaths occurred due to metastatic cancers in US alone. In developing countries, the death rates due to metastatic cancers are even higher due to the early stage diagnosis of cancer. Earlier, lesser therapies were available for increasing the progression of progression of patients with metastatic cancers and the metastatic cancer market.

However, a clear segment of Metastatic Cancer Therapy Market has emerged in the last few years with the arrival of products like Proven. Additionally, various immunotherapeutic agents have been included in this segment of the market such as Avastin, Herceptin, and Denosumab along with targeted drugs like afatinib, gefitinib, and erlotinib etc. for metastatic breast and lung cancer respectively. These are the most common types of cancers on the market ,

CAGR calculated on the basis of the market growth for each indication. Currently the metastatic cancer therapy market is well flourished with more than 10 unique products including advanced cancer therapies like targeted therapy, cancer vaccines, immunotherapies and some modern versions of chemotherapies like Jevtana. Additionally, more than 60 products are currently in the later phases of clinical pipeline with almost 60% in phase III and 37% in phase I & II of the clinical trial.

Eli Lilly product Alimta with average sales of US $ 2.5 trillion per year; Prolia by Amgen having US $ 1.9 trillion in just 9 months of 2017; Products of Roche Avastin and Herceptin are the top selling drugs of this segment having sales of US $ 5.2 trillion & US $ 5.4 trillion respectively in the year 2017.

In a high market size of the segment. Additionally, successive collaborations between large scale and small scale biotech firms, academia and pharmaceutical companies are entering into a wide range of unique products in metastatic cancer therapy market.

Read the full report  : https://www.bharatbook.com/drugs-market-research-reports-338296/metastatic-cancer-drug-global.html About Bharat Book Bureau:

Bharat Book Bureau is the leading market research report provider for market research reports, company profiles, industry reports, country reports, business reports, newsletters and online databases. Bharat Book Bureau delivers more than 400 publishers around the globe. We cover ourselves from Aeronautics to Zoology.

Contact us at: Bharat Book Bureau  Phone : +91 22 27810772/27810773 Email : poonam@bharatbook.com Website : www.bharatbook.com Follow us on : Twitter, Facebook, LinkedIn, Google Plus


Breast Cancer Therapeutics in Major Developed Markets to 2021 – Growth Driven by Rapid Uptake of Premium Priced Biologics, Worldwide Rising Incidence and The Most common Cancer in Women

Breast Cancer Therapeutics in Major Developed Markets to 2021 – Growth Driven by Rapid Uptake of Premium Priced Biologics and Rising Incidence Size and Share Published in 2015-12-15 Available for US$ 4995 at Researchmoz.us


Breast cancer, a malignant neoplasm, is the second most common cancer and the most common cancer in women worldwide, accounting for 16% of all female cancers, making the disease exceedingly prevalent. The number of women diagnosed with breast cancer has increased over the past few decades, but the number of deaths has declined due to earlier diagnosis and better treatment options.

Breast cancer treatment has been revolutionized in the past four decades, especially with increasing usage of targeted therapies. The marketed products landscape comprises a wide range of treatment options, including hormonal therapies, chemotherapies, combination therapies, and targeted therapies. Nevertheless, significant unmet need remains for products that can improve overall survival rate, time to disease progression, and overall response.


The current breast cancer market contains novel products, including Perjeta, a targeted therapy; Kadcyla, a human antibody-drug conjugate; and Halaven, a novel chemotherapeutic agent.

What are the competitive advantages of the existing novel drugs?

With over 700 active pipeline molecules, most of the investigational drug candidates are being evaluated for the first-line or second-line treatment of advanced-stage breast cancer, featuring new combination therapies, targeted therapies, and promising immunotherapies, as well as chemotherapy drug candidates.

Which classes of novel drugs are most prominent within the pipeline?

Is there strong potential for the pipeline to address unmet needs within the breast cancer market?

Analysis of clinical trials since 2006 identified that the failure rates of breast cancer molecules were highest in Phase II (41%), with the overall attrition rate for breast cancer in development being 61%.

How do failure rates vary by product stage of development, molecule type, and mechanism of action?

How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development?

Over the 2014–2021 forecast period, the breast cancer therapeutics market in the eight major markets is expected to increase in value at a CAGR of 7.3%, from $10.4 billion to over $17.2 billion.

Which markets make the most significant contribution to the current market size?

What are the epidemiology trends in these markets?

Will new market entrants lead to substantial changes in annual therapy costs?

How will different treatment usage patterns impact growth in the eight major markets?

Rising breast cancer incidence and new product approvals will lead to significant market growth over the forecast period, despite generic sales erosion resulting from patent expirations.

Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs?

Which patent expirations will have the most significant impact on the market?

Get a Sample Copy of the Report: http://www.researchmoz.us/enquiry.php?type=S&repid=536328

Reasons To Buy

This report will enable you to:

Understand the clinical context of breast cancer by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.

Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.

Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty.

Consider market opportunities and potential risks by examining trends in breast cancer clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.

Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in breast cancer by examining clinical trial data and multi-scenario product forecast projections.

Compare treatment usage patterns, annual therapy costs, and market growth projections for the US, Canada, the UK, France, Germany, Italy, Spain, and Japan.

Discover trends in licensing and co-development deals concerning breast cancer products and identify the major strategic consolidations that have shaped the commercial landscape.

Inquiry on this report: http://www.researchmoz.us/enquiry.php?type=E&repid=536328

Table of Content

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 7

1.2 List of Figures 7


2 Introduction 9

2.1 Disease Introduction 9

2.2 Symptoms 10

2.3 Etiology 10

2.4 Pathophysiology 11

2.5 Epidemiology 12

2.6 Diagnosis and Classification 14

2.7 Prognosis and Disease Staging 15

2.8 Treatment Options 17

2.8.1 Surgery and Radiation Therapy 18

2.8.2 Chemotherapy 18

2.8.3 Hormonal Therapies 19

2.8.4 Targeted Therapies 20

2.8.5 Resistance to Pharmacological Therapies 20

2.9 Treatment Guidelines 21

3 Marketed Products 24

3.1 Overview 24

3.1.1 Herceptin (trastuzumab) – Genentech 24

3.1.2 Perjeta (pertuzumab) – Genentech 26

3.1.3 Afinitor (everolimus) – Novartis 27

3.1.4 Tykerb/ Tyverb (lapatinib ditosylate monohydrate) – Novartis 28

3.1.5 Ibrance (palbociclib) – Pfizer 29

3.1.6 Ixempra (ixabepilone) – Bristol-Myers Squibb 29

3.1.7 Halaven (eribulin mesylate) – Eisai 30

3.1.8 Avastin (bevacizumab) – Genentech 31

3.1.9 Kadcyla (ado-trastuzumab emtansine) – Genentech 31

3.1.10 Marketed Products Heatmap 32

3.1.11 Measuring the Effectiveness of Treatment 38

3.2 Conclusion 39

Browse All Pharmaceutical Market Research Reports at: http://www.researchmoz.us/pharmaceutical-market-reports-38.html

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives.

Contact Us:

Mr. Nachiket Ghumare, +1-518-621-2074
USA-Canada Toll Free: 866-997-4948